Skip to content

BioSculpture Technology

BioSculpture Technology, Inc. is developing a disruptive, new minimally invasive procedure to treat Obesity, metabolic syndrome and Type 2 Diabetes mellitus, Endoscopic Visceral Lipectomy (“EVL”). EVL® has the potential of doing for bariatric surgery what LASIK did for vision correction. 

Our Corporate Mission is to unleash the artist in the surgeon® for cosmetic procedures, develop innovative solutions based on science™ for treatment applications,  and be a world leading manufacturer and developer of medical devices and procedures for handling adipose tissue targeting: the liposuction and body sculpting market, the bariatric treatment market, and the fat autograft and adipocyte-derived stem cell processing markets.